Strategic Alliances with PharmaJet
Many leading pharmaceutical, biotechnology, and academic institutions have formed strategic alliances with PharmaJet to use our needle-free injection systems to enhance the delivery of their injected medicines and vaccines.
Needle-free delivery provides a safe and often, more effective alternative to traditional injection techniques. We have needle-free devices for intradermal (ID), subcutaneous (SC), and intramuscular (IM) delivery in 0.5 ml and 0.1 mL dose volumes. Variable dose devices are in late stages of development.
Click on image to enlarge
Our Needle-free Injection Systems Effectively Deliver
✓ Low and high viscosity medicines
✓ Proteins and peptides
✓ Specialty drug therapies
✓ Nucleic acid-based vaccines and therapeutics
Ongoing Pre-Clinical Studies and Clinical Trials
Infectious Disease
COVID-19
Pre-Clinical Studies
DNA (12)
RNA (2)
Multiple (1)
Phase 1 Clinical Studies
DNA (6)
- BioNet Asia COVIGEN
- DIOSynVax
- Scancell COVIDITY
RNA (1)
Phase 2 Clinical Studies
DNA (1)
- Nykode VB D-01
Phase 3 Clinical Studies
DNA (1)
- Zydus Cadila ZyCoV-D
INFLUENZA
Pre-Clinical Studies
DNA (4)
Nanoparticle (1)
- Influenza
- Pandemic Influenza
- Swine Influenza
Phase 1 Clinical Studies
DNA (1)
- NIH VRC 316 (Influenza)
Phase 2 Clinical Studies
Phase 3 Clinical Studies
HIV/SIV
Pre-Clinical Studies
DNA (3)
- HIV
- SIV
Phase 1 Clinical Studies
DNA (3)
- INSERM/EuroVacc (HIV)
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Phase 2 Clinical Studies
Phase 3 Clinical Studies
ARBOVIRUSES
Pre-Clinical Studies
DNA (4)
- Crimean Congo
- Hemhorragic Fever
- VEEV
- Yellow fever
- Zika
Phase 1 Clinical Studies
Phase 2 Clinical Studies
DNA (1)
- NIH VRC 705 (Zika)
Phase 3 Clinical Studies
HANTAVIRUSES
Pre-Clinical Studies
DNA (1)
- Hantaviruses
Phase 1 Clinical Studies
DNA (1)
- USAMRIID CCHMC (Andes Virus)
Phase 2 Clinical Studies
DNA (1)
- USAMRIID WRAIR (Hantaan/Puumala)
Phase 3 Clinical Studies
OTHER VIRUSES
Pre-Clinical Studies
DNA (3)
RNA (1)
- Hepatitis B
- Marburg Virus
- PRRSV
- Smallpox
Phase 1 Clinical Studies
Phase 2 Clinical Studies
Phase 3 Clinical Studies
Therapeutics
CANCER
Pre-Clinical Studies
DNA (3)
- Canine Cancer
- Multiple Cancers
Phase 1 Clinical Studies
DNA (5)
- Duke University (Breast Cancer)
- Invectys (Therapeutic Cancer)
- MD Anderson (Lymphoma)
Phase 2 Clinical Studies
DNA (5)
- Evaxion EVX-02-001 (Melanoma)
- Invectys (Leukemia)
- Nykode VB C-02 (HPV)
- Nykode VB N-01 (Neoantigen)
- Nykode VB N-02 (Neoantigen)
RNA (1)
- Ludwig/CureVac/BI (Lung Cancer)
Phase 3 Clinical Studies
AUTOIMMUNE
Pre-Clinical Studies
DNA (1)
- Alzheimers
Phase 1 Clinical Studies
DNA (2)
- Alzheimers
- Vitiligo
Phase 2 Clinical Studies
Phase 3 Clinical Studies
Other Applications
VARIOUS INDICATIONS
Pre-Clinical Studies
DNA Platform (multiple)
mRNA Vaccines (multiple)
Other Injectables (multiple)
Phase 1 Clinical Studies
Subunit (1)
- Bleeding disorders
Phase 2 Clinical Studies
Phase 3 Clinical Studies
PharmaJet Vaccine Partnerships
We are interested in collaboration opportunities with partners where our technology can enhance the delivery of injectables in areas such as biologics, vaccines, small molecules, and other therapeutic technology platforms.
PharmaJet currently has active collaborations with a wide variety of partners including emerging biotechnology companies, established pharmaceutical companies, Armed Forces/DoD (Department of Defense), Federal Agencies, among others.
